Lesson plan
Fexlamose
Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.
Article summary
Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.